Cite
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.
MLA
Nanchahal, Jagdeep, et al. “Anti-Tumour Necrosis Factor Therapy for Early-Stage Dupuytren’s Disease (RIDD): A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Trial.” The Lancet. Rheumatology, vol. 4, no. 6, June 2022, pp. E407–16. EBSCOhost, https://doi.org/10.1016/S2665-9913(22)00093-5.
APA
Nanchahal, J., Ball, C., Rombach, I., Williams, L., Kenealy, N., Dakin, H., O’Connor, H., Davidson, D., Werker, P., Dutton, S. J., Feldmann, M., & Lamb, S. E. (2022). Anti-tumour necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial. The Lancet. Rheumatology, 4(6), E407–E416. https://doi.org/10.1016/S2665-9913(22)00093-5
Chicago
Nanchahal, Jagdeep, Catherine Ball, Ines Rombach, Lynn Williams, Nicola Kenealy, Helen Dakin, Heather O’Connor, et al. 2022. “Anti-Tumour Necrosis Factor Therapy for Early-Stage Dupuytren’s Disease (RIDD): A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Trial.” The Lancet. Rheumatology 4 (6): E407–16. doi:10.1016/S2665-9913(22)00093-5.